[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evotec Se (EVT.D.DX)

Evotec Se (EVT.D.DX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Evotec Se Essener Bogen 7 22419 Hamburg Hamburg 22419 DEU

P: +49 40560810

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Key Statistics

Overview:

Market Capitalization, $K 913,721
Shares Outstanding, K 177,594
% of Institutional Shareholders 22.05%

Financials:

Annual Sales, $ 788,373 K
Annual Net Income, $ -103,517 K
Last Quarter Sales, $ 156,644 K
Last Quarter Net Income, $ -121,936 K

Growth:

1-Year Return -48.57%
3-Year Return -79.08%
5-Year Return -86.29%
5-Year Revenue Growth 9.49%

Per-Share Information:

Most Recent Earnings -0.69 on 05/06/26
Next Earnings Date N/A
Earnings Per Share ttm -1.09
EPS Growth vs. Prev Year -7.69%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 08/18/00

EVT.D.DX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -24.06%
Return-on-Assets % -10.82%
Profit Margin % -13.13%
Debt/Equity 0.42
Price/Sales 1.18
Price/Cash Flow 47.91
Price/Book 1.28
Book Value/Share 3.94
Interest Coverage -5.01
60-Month Beta N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.